Research Activities During the Fellowship
Panu Wetwittayakhlang (9/11 papers as 1st author)
Accuracy of the Pancolonic Modified Mayo Score in predicting the long-term outcomes of ulcerative colitis: a promising scoring system. Bacsur P*, Wetwittayakhlang P*, Resál T, Földi E, Vasas B, Farkas B, Rutka M, Bessissow T, Afif W, Bálint A, Fábián A, Bor R, Szepes Z, Farkas K, Lakatos PL, Molnár T.Therap Adv Gastroenterol. 2024 Mar 21;17:17562848241239606. doi: 10.1177/17562848241239606. eCollection 2024.PMID: 38524790 Free PMC article.
Unravelling the Smoke Trail: Maternal Smoking, Childhood Exposure, and their Impact on Inflammatory Bowel Diseases. Wetwittayakhlang P, Lakatos PL.J Crohns Colitis. 2024 Mar 18:jjae032. doi: 10.1093/ecco-jcc/jjae032. Online ahead of print.PMID: 38498342 No abstract available.
Current Evidence for Combined Targeted Therapy for the Treatment of Inflammatory Bowel Disease. Wetwittayakhlang P, Lakatos PL.J Can Assoc Gastroenterol. 2023 Sep 26;7(1):22-29. doi: 10.1093/jcag/gwad032. eCollection 2024 Feb.PMID: 38314172 Free PMC article. Review.
Novel and emerging drugs for the treatment of Crohn’s disease: a review of phase II and III trials. Wetwittayakhlang P, Bessissow T, Lakatos PL.Expert Opin Emerg Drugs. 2024 Mar;29(1):19-34. doi: 10.1080/14728214.2024.2303116. Epub 2024 Jan 11.PMID: 38193191 Review.
Monitoring of Inflammatory Bowel Disease in Pregnancy: A Review of the Different Modalities. Al-Jabri R, Wetwittayakhlang P, Lakatos PL.J Clin Med. 2023 Nov 27;12(23):7343. doi: 10.3390/jcm12237343.PMID: 38068395 Free PMC article. Review.
Real-Life Efficacy of Tofacitinib in Various Situations in Ulcerative Colitis: A Retrospective Worldwide Multicenter Collaborative Study. Resál T, Bacsur P, Keresztes C, Bálint A, Bor R, Fábián A, Farkas B, Katsanos K, Michalopoylos G, Ribaldone DG, Attauabi M, Zhao M, Barak HA, Yanai H, Bezzio C, Rispo A, Castiglione F, Bar-Gil Shitrit A, Pugliese D, Armuzzi A, Savarino EV, Kolar M, Lukáš M, Chashkova E, Filip R, Rozieres A, Nancey S, Krznarić Ž, Schäfer E, Szamosi, Sarlós P, Franko M, Drobne D, Knyazev OV, Kagramanova AV, Limdi J, Wetwittayakhlang P, Lakatos PL, Maharshak N, Bannon L, Nyári T, Szepes Z, Farkas K; TFB Study Group; Molnár T.Inflamm Bowel Dis. 2023 Aug 5:izad135. doi: 10.1093/ibd/izad135. Online ahead of print.PMID: 37542737
Clinical efficacy and nocebo effect following non-medical biosimilar switch in patients with inflammatory bowel disease: A prospective observational study. Wetwittayakhlang P, Karkout K, Wongcha-Um A, Tselekouni P, Al-Jabri R, Afif W, Wild G, Bitton A, Bessissow T, Lakatos PL.Dig Liver Dis. 2024 Jan;56(1):35-42. doi: 10.1016/j.dld.2023.06.022. Epub 2023 Jul 5.PMID: 37419726
Mucosal Healing and Clinical Efficacy of Adalimumab in Small Intestinal Crohn’s Disease (SIMCHA Study): Final Results From a Prospective, Open-Label, Single-Arm Study. Wetwittayakhlang P, Verdon C, Starr M, Hahn GD, Golovics PA, Bessissow T, Afif W, Wild G, Bitton A, Lakatos PL.Turk J Gastroenterol. 2023 Jun;34(6):603-610. doi: 10.5152/tjg.2023.22527.PMID: 37162506 Free PMC article.
Time Trends of Environmental and Socioeconomic Risk Factors in Patients with Inflammatory Bowel Disease over 40 Years: A Population-Based Inception Cohort 1977-2020. Wetwittayakhlang P, Gonczi L, Golovics PA, Kurti Z, Pandur T, David G, Erdelyi Z, Szita I, Lakatos L, Lakatos PL.J Clin Med. 2023 Apr 21;12(8):3026. doi: 10.3390/jcm12083026.PMID: 37109362 Free PMC article.
Stable Incidence and Risk Factors of Colorectal Cancer in Ulcerative Colitis: A Population-Based Cohort Between 1977-2020. Wetwittayakhlang P, Golovics PA, Gonczi L, Lakatos L, Lakatos PL; VESZPREM EPIDEMIOLOGY STUDY GROUP.Clin Gastroenterol Hepatol. 2024 Jan;22(1):191-193.e3. doi: 10.1016/j.cgh.2023.03.022. Epub 2023 Mar 31.PMID: 37004972 Free article. No abstract available.
The Optimal Management of Inflammatory Bowel Disease in Patients with Cancer.Wetwittayakhlang P, Tselekouni P, Al-Jabri R, Bessissow T, Lakatos PL.J Clin Med. 2023 Mar 22;12(6):2432. doi: 10.3390/jcm12062432.PMID: 36983432
Reem Aljabri (4/2 papers as 1st author)
Paraskevi Tselekouni (2 papers)
Monitoring of Inflammatory Bowel Disease in Pregnancy: A Review of the Different Modalities. Al-Jabri R, Wetwittayakhlang P, Lakatos PL.J Clin Med. 2023 Nov 27;12(23):7343. doi: 10.3390/jcm12237343.PMID: 38068395 Free PMC article. Review.
Clinical efficacy and nocebo effect following non-medical biosimilar switch in patients with inflammatory bowel disease: A prospective observational study. Wetwittayakhlang P, Karkout K, Wongcha-Um A, Tselekouni P, Al-Jabri R, Afif W, Wild G, Bitton A, Bessissow T, Lakatos PL.Dig Liver Dis. 2024 Jan;56(1):35-42. doi: 10.1016/j.dld.2023.06.022. Epub 2023 Jul 5.PMID: 37419726
The Optimal Management of Inflammatory Bowel Disease in Patients with Cancer. Wetwittayakhlang P, Tselekouni P, Al-Jabri R, Bessissow T, Lakatos PL.J Clin Med. 2023 Mar 22;12(6):2432. doi: 10.3390/jcm12062432.PMID: 36983432
In moderately to severely active UC, etrasimod increased remission at 12 and 52 wk but increased adverse events. Al-Jabri R, Afif W.Ann Intern Med. 2023 Jul;176(7):JC82. doi: 10.7326/J23-0048. Epub 2023 Jul 4.PMID: 37399559